TSE:IMV - IMV Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$6.37 -0.06 (-0.93 %)
(As of 06/22/2018 08:00 AM ET)
Previous CloseC$6.43
Today's RangeC$6.29 - C$6.45
52-Week RangeC$3.33 - C$9.49
Volume83,134 shs
Average Volume42,165 shs
Market CapitalizationC$255.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.55
Immunovaccine Inc., a clinical-stage company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Rhino Resources Inc. and changed its name to Immunovaccine Inc. in September 2009. Immunovaccine Inc. was founded in 2000 and is based in Halifax, Canada.

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolTSE:IMV
CUSIPN/A
Phone+1-902-4921819

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares42,961,000

IMV (TSE:IMV) Frequently Asked Questions

What is IMV's stock symbol?

IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."

How were IMV's earnings last quarter?

Imv Inc (TSE:IMV) issued its earnings results on Monday, May, 14th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.01. The business earned $0.10 million during the quarter. View IMV's Earnings History.

When is IMV's next earnings date?

IMV is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for IMV.

What price target have analysts set for IMV?

1 analysts have issued 12 month price objectives for IMV's stock. Their forecasts range from C$10.40 to C$12.00. On average, they anticipate IMV's stock price to reach C$11.20 in the next year. View Analyst Ratings for IMV.

Who are some of IMV's key competitors?

Who are IMV's key executives?

IMV's management team includes the folowing people:
  • Mr. Frederic Ors, CEO & Director (Age 44)
  • Dr. Gabriela Nicola Rosu M.D., Chief Medical Officer
  • Mr. Leeladhar Sammatur, VP of Product Devel. & Manufacturing
  • Dr. Marc Mansour Ph.D., MBA, Consultant (Age 45)
  • Mr. Pierre Labbé, Chief Financial Officer (Age 53)

Has IMV been receiving favorable news coverage?

News articles about IMV stock have trended somewhat positive on Friday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. IMV earned a media sentiment score of 0.24 on Accern's scale. They also assigned news articles about the company an impact score of 46.20 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of IMV?

Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately C$6.37.

How big of a company is IMV?

IMV has a market capitalization of C$255.47 million.

How can I contact IMV?

IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.


MarketBeat Community Rating for IMV (IMV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  20 (Vote Underperform)
Total Votes:  43
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.